Peripheral neuropathy in children with type 1 diabetes

Diabetes and Metabolism

Volumn 38, Issue 4, 2012, Pages 281-289

  Louraki, M ^a   Karayianni, C ^a   Kanaka Gantenbein, C ^a   Katsalouli, M ^b   Karavanaki, K ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Children; Peripheral neuropathy; Review; Type 1 diabetes

Indexed keywords

CAPSAICIN; CARNITINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULOXETINE; GABAPENTIN; OPIATE; OXCARBAZEPINE; SOMATOMEDIN C; THIOCTIC ACID; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUPUNCTURE; AMPUTATION; ANALGESIA; CLINICAL EFFECTIVENESS; DAILY LIFE ACTIVITY; DIABETIC NEUROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; MORBIDITY; MORTALITY; NERVE CONDUCTION; NERVOUS SYSTEM PARAMETERS; NEUROPATHIC PAIN; PATHOGENESIS; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; QUALITY OF LIFE; REVIEW; RISK FACTOR; VIBRATION SENSATION THRESHOLD;

ADOLESCENT; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; EVOKED POTENTIALS, SOMATOSENSORY; FEMALE; HOT TEMPERATURE; HUMANS; MALE; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; SENSORY THRESHOLDS; SKIN; UNITED STATES; VIBRATION;

EID: 84866764443     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.02.006     Document Type: Review

References (111)

1. Sajic S., Petrovic R. Subclinical peripheral neuropathy in type 1 diabetic adolescents and its relationship with metabolic control. Srp Arh Celok Lek 2005, 133:358-362. [abstract].
2. Cho Y.H., Couper J.J., Donaghue K.C. Complications of childhood diabetes and the role of technology. Pediatr Endocrinol Rev. 2010, 7:422-431.
3. Marcovecchio M.L., Chiarelli F. Microvascular disease in children and adolescents with type 1 diabetes and obesity. Pediatr Nephrol. 2011, 26:365-375.
4. Gamstorp I., Shelburne S.A., Engleson G., Redondo D., Traisman H.S. Peripheral neuropathy in juvenile diabetes. Diabetes 1966, 15:411-418.
5. Nery Ferreira B.E., Silva I.N., de Oliveira J.T. High prevalence of diabetic polyneuropathy in a group of Brazilian children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2005, 18:1087-1094.
6. Thomas P.K. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes. 1997, 46:S54-S57.
7. Boulton A.J., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962.
8. Dyck P.J., Kratz K.M., Karnes J.L., Litchy W.J., Klein R., Pach J.M., et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993, 43:817-824.
9. Lee S.S., Han H.S., Kim H. A 5-yr follow-up nerve conduction study for the detection of subclinical diabetic neuropathy in children with newly diagnosed insulin-dependent diabetes mellitus. Pediatr Diabetes 2010, 11:521-528.
10. Karavanaki K., Baum J.D. Prevalence of microvascular and neurologic abnormalities in a population of diabetic children. J Pediatr Endocrinol Metab 1999, 12:411-422.
11. Vinik A.I., Pittenger G.L., McNitt P., Stansberry K.B. Diabetic neuropathies. An overview of clinical aspects, pathogenesis and treatment. Diabetes mellitus: A Fundamental and clinical text, 2nd edition 2000, 910-934. Lipincott, Williams and Wilkins, Philadelphia. D. Le Roith, S.I. Taylor, J.M. Olefsky (Eds.).
12. Mayhew J.A., Gillon K.R.W., Hawthorne J.N. Free and lipid inositol, sorbitol, and sugars in sciatic nerve obtained post-mortem from diabetic patients and control subjects. Diabetologia 1983, 24:13-15.
13. Mistry K.P., Beyer-Mears A., Diecke F.P. Mechanisms for D-glucose inhibition of myo-inositol influx into rat lens. Diabetes. 1993, 42:1737-1744.
14. Browlee M., Vlassara H., Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1985, 101:527-537.
15. Vlassara H., Browlee M., Cerami A. Recognition and uptake of human diabetic peripheral nerve myelin by macrophages. Diabetes 1985, 34:553-557.
16. Verrotti A., Guiva T., Morgese G., Chiarelli F. New trends in the etiopathogenesis of diabetic peripheral neuropathy. J Child Neurol 2001, 16:389-394.
17. Bierhaus A., Haslbeck K.M., Humpert P.M., Liliensiek B., Dehmer T., Morcos M., et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004, 114:1741-1751.
18. Bierhaus A., Schiekofer S., Schwaninger M., Andrassy M., Humpert P.M., Chen J., et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001, 50:2792-2808.
19. McLean W.G., Pekiner C., Cullum N.A., Casson I.F. Posttranslational modifications of nerve cytoskeletal proteins in experimental diabetes. Mol Neurobiol. 1992, 6:225-237.
20. Said G., Lacroix C., Lozeron P., Ropert A., Planté V., Adams D. Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain. 2003, 126:376-385.
21. Dashwood M.R., Thomas P.K. Neurovascular [125I]-ET-1 binding sites on human peripheral nerve. Endothelium. 1997, 5:119-123.
22. Kakizawa H., Itoh M., Itoh Y., Imamura S., Ishiwata Y., Matsumoto T., et al. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism. 2004, 53:550-555.
23. Trotta D., Verrotti A., Salladini C., Chiarelli F. Diabetic neuropathy in children and adolescents (Review). Pediatric Diabetes 2004, 5:44-57.
24. Stevens M.J. Nitric oxide as a potential bridge between the metabolic and vascular hypothesis of diabetic neuropathy. Diabet Med 1995, 12:292-295.
25. Strokov I.A., Bursa T.R., Drepa O.I., Zotova E.V., Nosikov V.V., Ametov A.S. Predisposing genetic factors for diabetic polyneuropathy in patients with type 1 diabetes: a population-based case-control study. Acta Diabetol 2003, 40:375-379.
26. Nicoloff G., Weiss A.S., Iotova V., Tzaneva V., Petrova C., Domuschieva N., et al. Abnormal levels of serum antielastin antibodies in children with diabetes mellitus type 1. J Investig Med 2006, 54:461-467.
27. Coste T.C., Gerbi A., Vague P., Maixent J.M., Pieroni G., Raccah D. Peripheral diabetic neuropathy and polyunsaturated fatty acid supplementations: natural sources or biotechnological needs?. Cell Mol Biol. 2004, 50:845-853.
28. Cai F., Helke C.J. Abnormal PI3 kinase/Akt signal pathway in vagal afferent neurons and vagus nerve of streptozotocin-diabetic rats. Brain Res Mol Brain Res. 2003, 110:234-244.
29. Middlemas A., Delcroix J.D., Sayers N.M., Tomlinson D.R., Fernyhough P. Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3. Brain. 2003, 126:1671-1682.
30. Marcovecchio M.L., Tossavainen P.H., Dunger D.B. Prevention and treatment of microvascular disease in childhood type 1 diabetes. Br Med Bull. 2010, 94:145-164.
31. Levy D.M., Abraham R.R., Abraham R.M. Small and large fibre involvement in early diabetic neuropathy: A study with the median plantar response and sensory thresholds. Diabetes Care 1987, 10:441-447.
32. Greene D.A. Metabolic abnormalities in diabetic peripheral nerve: relation to impaired function. Metabolism 1983, 32:118-123.
33. Charles M., Soedamah-Muthu S.S., Tesfaye S., Fuller J.H., Arezzo J.C., Chaturvedi N., et al. Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2010, 33:2648-2653.
34. Vinik A.I., Ullal J., Parson H.K., Casellini C.M. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab. 2006, 2:269-281.
35. Sorensen L., Molyneaux L., Yue D.K. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care. 2006, 29:883-887.
36. Ziegler D., Mayer P., Gries F.A. Evaluation of thermal, pain and vibration sensation thresholds in newly diagnosed type 1 diabetic patients. J Neurol Psychiatr 1988, 51:1420-1424.
37. Melton J.L., Dyck P.J. Epidemiology. Diabetic neuropathy 1987, 27-35. WB Saunders, Philadelphia. P.J. Dyck, P.K. Thomas, A.K. Asbury (Eds.).
38. Hendriksen P.H., Oey P.L., Wieneke G.H., Bravenboer B., van Huffelen A.C. Subclinical diabetic polyneuropathy: early detection of involvement of different nerve fibre types. J Neurol Neuros Psyc 1993, 56:509-514.
39. Dyck P.J., Dyck P.J.B., Velosa J.A., Larson T.S., O'Brien P.C. Patterns of Quantitative Sensation Testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy. Diabetes Care 2000, 23:510-517. The Nerve Growth Factor Study Group.
40. Meh D., Denislic M. Subclinical neuropathy in type I diabetic children. Electroencephalogr Clin Neurophysiol. 1998, 109:274-280.
41. Papanas N., Maltezos E. The diabetic hand: a forgotten complication?. J Diabetes Complications. 2010, 24:154-162.
42. Consensus Statement Report and recommendations of San Antonio Conference on diabetic neuropathy: American Diabetes Association/American Academy of Neurology. Diabetes Care 1988, 11:592-597.
43. Kimura J. Electrodiagnosis in disease of nerve and muscle: principles and practice 1989, FA Davis, Philadelphia.
44. Daube J.R. Electrophysiologic testing in diabetic neuropathy. Diabetic neuropathy 1987, 162. W.B. Saunders, Philadelphia. P.J. Dyck, P.K. Thomas, A.K. Asbury (Eds.).
45. Uzun N., Uluduz D., Mikla S., Aydin A. Evaluation of asymptomatic central neuropathy in type I diabetes mellitus. Electromyogr Clin Neurophysiol 2006, 46:131-137.
46. Hemmi S., Inoue K., Murakami T., Sunada Y. Comparison of the sensitivities of plantar nerve conduction techniques for early detection of diabetic sensory polyneuropathy. Electromyogr Clin Neurophysiol. 2010, 50:269-275.
47. Dyck P.J., Overland C.J., Low P.A., Litchy W.J., Davies J.L., Dyck P.J., et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: clinical vs. neurophysiological trial. Muscle Nerve 2010, 42:157-164.
48. Turgut N., Karasalihoglu S., Kucukugurluoglu Y., Balci K., Ekuklu G., Tutunculer F. Clinical utility of dorsal sural nerve conduction studies in healthy and diabetic children. Clin Neurophysiol 2004, 115:1452-1456.
49. Lacomis D. Small-fiber neuropathy. Muscle Nerve. 2002, 26:173-188.
50. Davis E.A., Jones T.W., Walsh P., Byrne G.C. The use of biothesiometry to detect neuropathy in children and adolescents with IDDM. Diabetes Care 1997, 20:1448-1453.
51. Nelson D., Mah J.K., Adams C., Hui S., Crawford S., Darwish H., et al. Comparison of conventional and non-invasive techniques for the early identification of diabetic neuropathy in children and adolescents with type 1 diabetes. Ped Diab 2006, 7:305-310.
52. Martin C.L., Waberski B.H., Pop-Busui R., Cleary P.A., Catton S., Albers J.W., et al. Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study. Diabetes Care. 2010, 33:2635-2641.
53. Perkins B.A., Olaleve D., Zinman B., Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001, 24:250-256.
54. Kramer H.H., Rolke R., Bickel A., Birklein F. Thermal thresholds predict painfulness of diabetic neuropathies. Diabetes Care 2004, 27:2386-2391.
55. Bao X.H., Wong V., Wang Q., Low L.C. Prevalence of peripheral neuropathy with insulin-dependent diabetes mellitus. Pediatr Neurol 1999, 20:204-209.
56. Nordwall M., Hyllienmark L., Ludvigsson J. Early diabetic complications in a population of young patients with T1DM despite intensive treatment. J Ped End Met 2006, 19:45-54.
57. Cenesiz F., Tur B.S., Tezic T., Gurer Y. Nerve conduction in children suffering insulin dependent diabetes mellitus. Indian J Pediatr 2003, 70:945-951.
58. Martin C.L., Waberski B.H., Pop-Busui R., Cleary P.A., Catton S., Albers J.W., et al. Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study. Diabetes Care 2010, 33:2635-2641.
59. Sosenko J.M., Kato M., Soto R.A., Gadia M.T., Ayyar D.R. Specific assessments of warm and cool sensitivities in adult diabetic patients. Diabetes Care 1988, 11:481-483.
60. Olsen B.S., Sjolie A., Hougaard P., Johannesen J., Borch-Johnsen K., Marinelli K., et al. A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood. J Diabetes Complications 2000, 14:295-300.
61. Abad F., Diaz-Gomez N.M., Rondriguez I., Perez R., Delgado J.A. Subclinical pain and thermal sensory dysfunction in children and adolescents with Type 1 diabetes mellitus. Diabetic Med 2002, 19:827-831.
62. Brink S.J. Complications of pediatric and adolescent type 1 diabetes mellitus. Curr Diab Rep 2001, 1:47-55.
63. Morales A. A better future for children with type 1 diabetes: review of the conclusions from the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. J Ark Med Soc. 2009, 106:90-93.
64. White N.H., Waltman S.R., Krupin T., Sandiago J.V. Reversal of neuropathic and gastrointestinal complications related to diabetes mellitus in adolescents with improved metabolic control. J Paediatr 1981, 99:41-45.
65. The Diabetes Control Complications Trial Research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in IDDM. N Engl J Med 1993, 329:977-986.
66. Perkins B.A., Greene D.A., Bril V. Glycemic control is related to the morphological severity of diabetic sensorimotor polyneuropathy. Diabetes Care. 2001, 24:748-752.
67. Weintrob N., Amitay I., Lilos P., Shalitin S., Lazar L., Josefberg Z. Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes. J Diabetes Complications 2007, 21:13-19.
68. Solders G., Thalme B., Aguirre-Aquino M., Brandt L., Berg U., Persson A. Nerve conduction and autonomic nerve function in diabetic children. A 10-year follow-up study. Acta Paediatr 1997, 86:361-366.
69. Lee S.S., Han H.S., Kim H. A 5-yr follow-up nerve conduction study for the detection of subclinical diabetic neuropathy in children with newly diagnosed insulin-dependent diabetes mellitus. Pediatr Diabetes. 2010, 11:521-528.
70. Albers J.W., Herman W.H., Pop-Busuli R., Feldman E.L., Martin C.L., Cleary P.A., et al. Effect of prior intensive treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010, 33:1090-1096.
71. Barkai L., Kempler P., Vamosi I., Lukacs K., Marton A., Keresztes K. Peripheral sensory nerve dysfunction in children and adolescents with type 1 diabetes mellitus. Diabetes Med 1998, 15:228-233.
72. Sosenko J.M., Boulton A.J., Kubrusly D.B., Weintraub J.K., Skyler J.S. The vibratory perception threshold in young diabetic patients: associations with glycaemia and puberty. Diabetes Care 1985, 8:605-607.
73. Gallai V., Firenze C., Mazzotta G., Del Gatto F. Neuropathy in children and adolescents with diabetes mellitus. Acta Neurol Scand 1988, 78:136-140.
74. The DCCT Research Group Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of diabetes control and complications trial (DCCT). Diabetes 1988, 37:476-481.
75. Bloom S., Till S., Sonksen P., Smith S. Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects. BMJ 1984, 288:1793-1795.
76. Karsidag S., Morali S., Sargin M., Salman S., Karsidag K., Us O. The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed T1DM. Diab Res Clin Pract 2005, 67:211-219.
77. Ludvigsson J., Johannesson G., Heding L., Hager A., Larsson Y. Sensory nerve conduction velocity and vibratory sensibility in Juvenile Diabetics. Acta Paediatr Scand 1979, 68:739-743.
78. Monti M.C., Lonsdale J.T., Montomoli C., Montross R., Schlag E., Greenberg D.A. Familial risk factors for microvascular complications and differential male-female risk in a large cohort of American families with type 1 diabetes. J Clin Endocrinol Metab 2007, 92:4650-4655.
79. Williamson J.R., Chang K., Rowold E., Marvel J., Tominson M., Kilo C. Diabetes-induced increases in vascular permeability are prevented by castration and by sorbinil (abstract). Diabetes 1985, 34(Suppl. 1):108A.
80. Duck S., Wei F., Parke J., Swick H. Role of height and glycosylated hemoglobin in abnormal nerve conduction in pediatric patients with T1DM after 4-9 Yr of disease. Diabetes Care 1991, 14:386-392.
81. El Bahri-Ben Mrad F., Gouider R., Fredj M., Ben Becher S., Mrad-Mazigh S., Mrabet A. Childhood diabetic neuropathy: a clinical and electrophysiological study. Funct Neurol. 2000, 15:35-40.
82. Barkai L., Kempler P. Puberty as a risk factor for diabetic neuropathy. Diabetes Care 2000, 23:1044-1045.
83. Sosenko J.M., Miettinen O.S., Williamson J.R., Gabbay K.H. Muscle capillary basement membrane thickness and long-term glycaemia in type 1 diabetes mellitus. N Engl J Med 1984, 31:694-698.
84. Merimee T.J., Zapf J., Froesch E.R. Insulin-like growth factors: studies in diabetics with and without retinopathy. N Engl J Med 1983, 309:527-530.
85. Riihimaa P.H., Suominen K., Tolonen U., Jantti V., Knip M., Tapanainen P. Peripheral nerve function is increasingly impaired during puberty in adolescents with type 1 diabetes. Diabetes Care 2001, 24:1087-1092.
86. Mohsin F., Craig M.E., Cusumano J., Chan A.K., Hing S., Lee J.W., et al. Discordant trends in microvascular complications in adolescents with type 1 diabetes from 1990 to 2002. Diabetes Care. 2005, 28:1974-1980.
87. Otto-Buczkowska E., Kazibutowska Z., Sołtyk J., Machnica L. Neuropathy and type 1 diabetes mellitus. Pediatr Endocrinol Diabetes Metab. 2008, 14:109-116. [abstract].
88. Olsen B.S., Johannesen J., Sjolie A., Borch-Johnsen K., Hougaard P., Thorsteinsson B., et al. Metabolic control and prevalence of microvascular complications in young Danish patients with Type 1 diabetes mellitus. Diabet Med 1999, 16:79-85.
89. Young R.J., Ewing D.J., Clark B.F. Nerve function and metabolic control in teenage diabetics. Diabetes 1983, 32:142-147.
90. Dorchy H. Screening for subclinical complications in young type 1 diabetic patients: experience acquired in Brussels. Pediatr Endocrinol Rev 2004, 1:380-403.
91. White N.H., Waltman S.R., Krupin T., Santiago J.V. Reversal of neuropathic and gastrointestinal complications related to diabetes mellitus in adolescents with improved metabolic control. J Pediatrics 1981, 99:41-45.
92. Watkins P.J., Thomas P.K. Diabetes mellitus and the nervous system. J Neurol Neurosurg Psychiatry 1998, 65:620-632.
93. Boulton A.J. Treatments for diabetic neuropathy. Curr Diab Rep. 2001, 1:127-132.
94. Tesfaye S. Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care. 2009, 3:136-143.
95. Carrazana E., Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage. 2003, 25(5 Suppl.):S31-S35.
96. Gore M., Tai K.S., Zlateva G., Bala Chandran A., Leslie D. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. Pain Pract 2011, 11(6):528-539.
97. Harati Y., Gooch C., Swenson M., Edelman S.V., Greene D., Raskin P., et al. Maintenance of the long term efficacy of tramadol for the treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000, 14:65-70.
98. Vallianou N., Evangelopoulos A., Koutalas P. Alpha-lipoic acid and diabetic neuropathy. Rev Diabet Stud. 2009, 6:230-236.
99. Ziegler D., Nowak H., Kempler P., Vargha P., Low P.A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004, 21:114-121.
100. Ziegler D., Ametov A., Barinov A., Dyck P.J., Gurieva I., Low P.A., et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006, 29:2365-2370.
101. Ziegler D., Low P.A., Boulton A.J.M., Vinik Al, Freeman R., Samigullin R., et al. Effect of 4-year antioxidant treatment with a-lipoic acid in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes 2007, 56(Suppl. 1):A2.
102. Nicolucci A., Carinci F., Cavaliere D., Scorpiglione N., Belfiglio M., Labbrozzi D., et al. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St.-Vincent Declaration. Diabet Med. 1996, 13:1017-1026.
103. Donaghue K.C., Silink M. Diabetic neuropathy in childhood: review. Diabetes Nutr Metab. 1999, 12:154-160.
104. Sugimoto K., Yasujima M., Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008, 14:953-961.
105. Malik R.A., Williamson S., Abbott C.A. Effects of the angiotensin-converting enzyme inhibitor trandanopril on human diabetic neuropathy: a randomized controlled trial. Lancet 1998, 352:1979-1981.
106. Kamiya H., Murakawa Y., Zhang W., Sima A.A. Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes Metab Res Rev. 2005, 21:448-458.
107. Sima A.A., Zhang W., Li Z.G., Murakawa Y., Pierson C.R. Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes. 2004, 53:1556-1563.
108. Uzun N., Sarikaya S., Uluduz D., Aydin A. Peripheric and automatic neuropathy in children with type 1 diabetes mellitus: the effect of L-carnitine treatment on the peripheral and autonomic nervous system. Electromyogr Clin Neurophysiol. 2005, 45:343-351.
109. Geraldes P., King G.L. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010, 106(8):1319-1331.
110. Liu W.J., Jin H.Y., Lee K.A., Xie S.H., Baek H.S., Park T.S. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol 2011, 164(5):1410-1420.
111. Peeraer E., Van Lutsenborg A., Verheyen A., De Jongh R., Nuydens R., Meert T.F. Pharmacological evaluation of rat dorsal root ganglion neurons as an in vitro model for diabetic neuropathy. J Pain Res. 2011, 14:55-65.